Eslicarbazepine Acetate response in Intellectual Disability population versus general population

BACKGROUND A quarter of people with intellectual disability (ID) have epilepsy, compared to approximately one in a hundred across the general population. Evidence for the safe and effective prescibing of anti-epileptic drugs (AEDs) for those with ID is however limited. AIMS OF STUDY This study seeks to strengthen the research evidence around Eslicarbazepine Acetate (ESL), a new AED, by comparing response of individuals with ID to those from the general population who do not have ID. METHODS A single dataset was created through retrospective data collection from English and Welsh NHS Trusts. The UK based Epilepsy Database Research Register (Ep-ID) data collection and analysis method were used. RESULTS Data were collected for 93 people (36 ID and 57 'no ID'). Seizure improvement of '>50%' was higher at 12 months for 'no ID' participants (56%), compared to ID participants (35%). Retention rates were slightly higher for those with ID (56% compared to 53%). Neither difference were significant. CONCLUSIONS Tolerance and Efficacy for ID and 'no ID' people in our dataset were similar. Seizure improvement and retention rates were slightly lower than that found in other European datasets, but findings strengthen the evidence for the use of ESL in the ID population.